Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept Dosing Regimens for CRVO-Related Macular Edema in Ethnic Minority Areas
ChiCTR2500107035Phase 4Not yet recruiting
- Sponsor
- Chaoju Eye Care
- Start
- Aug 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of conbercept in macular edema and central retinal vein occlusion (CRVO) (2 arms), sponsored by Chaoju Eye Care. Primary endpoints: Best corrected visual acuity (BCVA) and Macular foveal thickness (CMT). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
conbercept
03
Conditions
macular edemacentral retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on ChiCTR2500107035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107035.